Kura Oncology, Inc. (KURA)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
12.66 USD
-0.52
(-3.945%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 12.70 +0.04 (0.312%) ⇧ (Aug. 28, 2026, 7:39 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:38 a.m. EDT
The investment case here is fundamentally broken despite the optimistic analyst consensus. The company is burning cash at an alarming rate, generating negative free cash flow of nearly $166 million against a tiny market cap of roughly $1 billion. The balance sheet is fragile, with operating losses eroding equity and no visible path to profitability in the immediate term. While revenue growth of 36.5% looks impressive on paper, the gross and operating margins are deeply negative, indicating that the cost of goods sold and R&D are consuming all incremental revenue. The price action confirms this distress; after a massive spike in 2024, the stock has collapsed over 60% year-over-year, trading near its 52-week lows. The options market is screaming 'sell,' with traders piling into protective puts at strikes far below the current price, suggesting they expect further deterioration. The disconnect between the 'strong buy' analyst ratings and the reality of the financials—negative EPS, negative ROE, and a lack of sustainable margins—is dangerous. Investors are likely buying the hype of potential drug approvals, but the financial engine is stalled. Until the company demonstrates a clear path to positive cash flow or a massive, game-changing milestone that justifies the current valuation premium, this remains a speculative trap. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.091056 |
| AutoARIMA | 0.091132 |
| AutoETS | 0.097382 |
| AutoTheta | 0.098251 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 4.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.520 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 50.495 |
| Revenue per Share | 0.875 |
| Market Cap | 1,126,241,408 |
| Forward P/E | -5.62 |
| Beta | 0.38 |
| Website | https://kuraoncology.com |
As of Aug. 22, 2026, 2:38 a.m. EDT: Speculators are aggressively betting on a crash, with massive volume flowing into deep out-of-the-money puts (strikes $4-$7) for January 2027, while call activity is concentrated in the money or at-the-money. This heavy put positioning suggests a fear of significant downside rather than a bullish expectation of a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6578616 |
| Address1 | 4,930 Directors Place |
| Address2 | Suite 500 |
| All Time High | 43.0 |
| All Time Low | 2.5 |
| Ask | 16.32 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,946,220 |
| Average Daily Volume3 Month | 1,843,766 |
| Average Volume | 1,843,766 |
| Average Volume10Days | 2,946,220 |
| Beta | 0.381 |
| Bid | 12.65 |
| Bid Size | 3 |
| Board Risk | 8 |
| Book Value | 0.544 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.66 |
| Current Ratio | 4.733 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 13.17 |
| Day Low | 12.62 |
| Debt To Equity | 50.495 |
| Display Name | Kura Oncology |
| Earnings Call Timestamp End | 1,786,566,600 |
| Earnings Call Timestamp Start | 1,786,566,600 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -316,799,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.994 |
| Enterprise To Revenue | 8.18 |
| Enterprise Value | 631,671,424 |
| Eps Current Year | -3.1875 |
| Eps Forward | -2.25111 |
| Eps Trailing Twelve Months | -3.24 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.7772 |
| Fifty Day Average Change | 1.8828001 |
| Fifty Day Average Change Percent | 0.17470217 |
| Fifty Two Week Change Percent | 65.786156 |
| Fifty Two Week High | 13.9 |
| Fifty Two Week High Change | -1.2399998 |
| Fifty Two Week High Change Percent | -0.08920862 |
| Fifty Two Week Low | 7.358 |
| Fifty Two Week Low Change | 5.302 |
| Fifty Two Week Low Change Percent | 0.7205763 |
| Fifty Two Week Range | 7.358 - 13.9 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,410,200,000 |
| Float Shares | 70,438,129 |
| Forward Eps | -2.25111 |
| Forward P E | -5.623892 |
| Free Cashflow | -165,880,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 260 |
| Fullday Change | -0.52 |
| Fullday Change Percent | -3.94538 |
| Fullday Price | 12.6995 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -2.3672 |
| Gross Profits | -182,807,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01387 |
| Held Percent Institutions | 0.99623 |
| Implied Shares Outstanding | 88,960,619 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California. |
| Long Name | Kura Oncology, Inc. |
| Market | us_market |
| Market Cap | 1,126,241,408 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_282774456 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -296,775,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,171,611,352 |
| Number Of Analyst Opinions | 12 |
| Open | 13.05 |
| Operating Cashflow | -111,757,000 |
| Operating Margins | -3.4976501 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 500 8800 |
| Post Market Change | 0.039500237 |
| Post Market Change Percent | 0.3120082 |
| Post Market Price | 12.6995 |
| Post Market Time | 1,787,960,370 |
| Previous Close | 13.18 |
| Price Eps Current Year | -3.9717646 |
| Price Hint | 2 |
| Price To Book | 23.272057 |
| Price To Sales Trailing12 Months | 14.583897 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.502 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.52 |
| Regular Market Change Percent | -3.94538 |
| Regular Market Day High | 13.17 |
| Regular Market Day Low | 12.61 |
| Regular Market Day Range | 12.61 - 13.17 |
| Regular Market Open | 13.05 |
| Regular Market Previous Close | 13.18 |
| Regular Market Price | 12.66 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,805,273 |
| Return On Assets | -0.31303 |
| Return On Equity | -1.67709 |
| Revenue Growth | 0.365 |
| Revenue Per Share | 0.875 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 88,960,619 |
| Shares Percent Shares Out | 0.1475 |
| Shares Short | 13,124,869 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 13,732,567 |
| Short Name | Kura Oncology, Inc. |
| Short Percent Of Float | 0.1515 |
| Short Ratio | 10.03 |
| Source Interval | 15 |
| State | CA |
| Symbol | KURA |
| Target High Price | 76.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 32.0 |
| Target Median Price | 28.0 |
| Total Cash | 519,024,992 |
| Total Cash Per Share | 5.834 |
| Total Debt | 24,455,000 |
| Total Revenue | 77,225,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.74145 |
| Two Hundred Day Average Change | 2.9185495 |
| Two Hundred Day Average Change Percent | 0.29960114 |
| Type Disp | Equity |
| Volume | 1,805,273 |
| Website | https://kuraoncology.com |
| Zip | 92,121 |